局部晚期宫颈癌放化疗联合图像引导自适应近距离放疗后医生评估与患者报告泌尿系统发病率
EMBRACE研究为前瞻性多中心研究,分析1176例局部晚期宫颈癌患者接受MRI引导自适应近距离放疗后泌尿系统发病率,中位随访27个月。医生评估3-4级泌尿系统发病率 actuarial 3年发生率为5.3%,患者报告以尿频和漏尿为常见症状且随时间波动。
要点
- 3年时医生评估2-4级尿频/尿急、尿失禁、膀胱炎患病率分别为4.3%、5.0%、1.7%。
- 患者报告「相当多」或「非常多」困扰的尿频比例在14.0%至21.5%间波动。
- 3年时3-4级泌尿系统 actuarial 发生率为5.3%,无5级毒性发生。
核心结论
- 图像引导自适应近距离放疗相关的3-4级泌尿系统发病率有限。
- 2-4级泌尿系统发病率主要包括尿频/尿急、尿失禁和膀胱炎,在患者报告中具有相当高的患病率。
- 不同泌尿系统发病率终点具有不同的表现模式和时间进程。
研究设计与样本
- EMBRACE研究为前瞻性多中心研究,评估MRI引导自适应近距离放疗在局部晚期宫颈癌中的应用。
- 共分析1176例患者,中位随访27个月(范围1-83个月)。
- 医生评估采用CTCAE v.3,患者报告采用EORTC QLQ-C30和CX24问卷,在基线和随访期间前瞻性评估。
主要发现
- 3年时医生评估2-4级尿频/尿急、尿失禁、膀胱炎的患病率分别为4.3%、5.0%、1.7%;1-4级患病率分别为24.5%、16.1%、5.8%。
- 患者报告最频繁的终点为「尿频」和「漏尿」;「相当多」或「非常多」困扰的尿频比例在14.0%至21.5%之间波动,漏尿从基线4.6%增加至3年时9.3%。
- 3-4级泌尿系统发病率的 actuarial 3年发生率为5.3%,大多数事件为尿频、尿失禁和输尿管狭窄;3年和5年时3-4级瘘管、出血、痉挛和膀胱炎均低于1.0%。
- 未发生5级毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The EMBRACE study is a prospective multi-institutional study on MRI guided adaptive brachytherapy (IGABT) in locally advanced cervix cancer (LACC). This analysis describes early to late urinary morbidity assessed by physicians and patients (PRO). MATERIAL AND METHODS: A total of 1176 patients were analysed. Median follow up (FU) was 27 (1-83) months. Morbidity (CTCAE v.3) and PRO (EORTC QLQ-C30&CX24) was prospectively assessed at baseline (BL), and during FU. RESULTS: The most frequent symptoms were frequency/urgency, incontinence, and cystitis with grade 2-4 prevalence rates of 4.3%, 5.0% and 1.7% and grade 1-4 prevalence rates of 24.5%, 16.1% and 5.8% at 3-years. The most frequent PRO endpoints were "urinary frequency" and "leaking of urine". Prevalence of "Quite a bit" or "very much" bother fluctuated from 14.0% to 21.5% for "frequency", while "leaking of urine" increased from 4.6% at BL to 9.3% at 3-years. Actuarial 3-year incidence of grade 3-4 urinary morbidity was 5.3% with most events being urinary frequency, incontinence and ureteral strictures. Grade 3-4 fistula, bleeding, spasm and cystitis were all <1.0% at 3/5-years. No grade 5 toxicity occurred. CONCLUSION: Urinary grade 3-4 morbidity with IGABT was limited. Urinary morbidity grade 2-4 comprises mainly frequency/urgency, incontinence and cystitis and has considerable prevalence in PRO. Various urinary morbidity endpoints have different patterns of manifestation and time course.
引用
- Fokdal L, Pötter R, Kirchheiner K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018. PMID: 29784450. doi:10.1016/j.radonc.2018.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。